Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Alzheimer disease

Perceived efficacy of antidementia drug treatment

Nature Reviews Neurology volume 5, pages 302–303 (2009)Cite this article

Investigators in Germany have solicited the views of neurologists and psychiatrists on the effectiveness of antidementia drug treatments. The study concludes that clinicians generally consider these treatments to be beneficial, and that the provision of support to caregivers seems to further enhance the perceived benefits.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Alzheimer's Society. Dementia UK report [online] (2007).

  2. National Institute for Health and Clinical Excellence. Alzheimer's disease—donepezil, galantamine, rivastigmine (review) and memantine [online] (2007).

  3. National Institute for Health and Clinical Excellence. Dementia: supporting people with dementia and their carers in health and social care [online] (2006).

  4. Waldemar, G. et al. Access to diagnostic evaluation and treatment for dementia in Europe. Int. J. Geriatr. Psychiatry 22, 47–54 (2007).

    Article  Google Scholar 

  5. Oude Voshaar, R. C., Burns, A. & Olde Rikkert, M. G. European Dementia Consensus Network Group (EDCON). Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs. Int. J. Geriatr. Psychiatry 21, 29–31 (2006).

    Article  Google Scholar 

  6. Hallauer, J. F. Supply deficits in Alzheimer's disease [German]. Arzneimittel-Forschung (Drug Res.) 52, 4–12 (2002).

    Google Scholar 

  7. Riepe, M. W. & Ibach, B. Neurological and psychiatric practitioners' views on Alzheimer's disease and treatment thereof. Dement. Geriatr. Cogn. Disord. 26, 541–546 (2008).

    Article  CAS  Google Scholar 

  8. Department of Health. Living well with dementia: a National Dementia Strategy [online] (2009).

  9. Burns, A. & Iliffe, S. Alzheimer's disease. BMJ 338, b158 (2009).

    Article  Google Scholar 

  10. Burns, A. & Robert, P. The National Dementia Strategy in England. BMJ 338, b931 (2009).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Manchester Psychiatry Research Group, Manchester, UK

    Kevina McAvinchey & Alistair Burns

Authors
  1. Kevina McAvinchey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alistair Burns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alistair Burns.

Ethics declarations

Competing interests

K. McAvinchey declares no competing interests. A. Burns has acted as a consultant for Baxter, Eisai, Janssen-Cilag, Lundbeck, Novartis, Pfizer and Shire.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McAvinchey, K., Burns, A. Perceived efficacy of antidementia drug treatment. Nat Rev Neurol 5, 302–303 (2009). https://doi.org/10.1038/nrneurol.2009.56

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2009.56

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing